|
Sep 23
|
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
|
|
Sep 17
|
Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)’s Oncology Portfolio is Beautiful
|
|
Sep 16
|
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
|
|
Sep 16
|
ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years
|
|
Sep 16
|
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
|
|
Sep 13
|
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
|
|
Sep 13
|
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
|
|
Sep 5
|
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
|
|
Sep 5
|
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
|
|
Sep 5
|
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Aug 27
|
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
|
|
Aug 26
|
HRMY or REGN: Which Is the Better Value Stock Right Now?
|
|
Aug 26
|
Regeneron gains European approval for bispecific lymphoma drug
|
|
Aug 26
|
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
|
Aug 26
|
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
|
|
Jul 30
|
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
|
|
Jul 30
|
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Jul 30
|
Roche’s Vabysmo challenges Eylea dominance with third European indication
|
|
Jul 30
|
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems
|